Transforming Growth Factor β1/Smad4 Signaling Affects Osteoclast Differentiation via Regulation of miR-155 Expression

  • Zhao, Hongying (Department of Pharmacy, Zhejiang Provincial People's Hospital) ;
  • Zhang, Jun (Department of Orthopedics, Zhejiang Provincial People's Hospital) ;
  • Shao, Haiyu (Department of Orthopedics, Zhejiang Provincial People's Hospital) ;
  • Liu, Jianwen (Department of Orthopedics, Zhejiang Provincial People's Hospital) ;
  • Jin, Mengran (Department of Orthopedics, Zhejiang Provincial People's Hospital) ;
  • Chen, Jinping (Department of Orthopedics, Zhejiang Provincial People's Hospital) ;
  • Huang, Yazeng (Department of Orthopedics, Zhejiang Provincial People's Hospital)
  • Received : 2016.12.12
  • Accepted : 2017.02.22
  • Published : 2017.03.31


Transforming growth factor ${\beta}1$ $(TGF{\beta}1)/Smad4$ signaling plays a pivotal role in maintenance of the dynamic balance between bone formation and resorption. The microRNA miR-155 has been reported to exert a significant role in the differentiation of macrophage and dendritic cells. The goal of this study was to determine whether miR-155 regulates osteoclast differentiation through $TGF{\beta}1/Smad4$ signaling. Here, we present that $TGF{\beta}1$ elevated miR-155 levels during osteoclast differentiation through the stimulation of M-CSF and RANKL. Additionally, we found that silencing Smad4 attenuated the upregulation of miR-155 induced by $TGF{\beta}1$. The results of luciferase reporter experiments and ChIP assays demonstrated that $TGF{\beta}1$ promoted the binding of Smad4 to the miR-155 promoter at a site located in 454 bp from the transcription start site in vivo, further verifying that miR-155 is a transcriptional target of the $TGF{\beta}1/Smad4$ pathway. Subsequently, TRAP staining and qRT-PCR analysis revealed that silencing Smad4 impaired the $TGF{\beta}1$-mediated inhibition on osteoclast differentiation. Finally, we found that miR-155 may target SOCS1 and MITF to suppress osteoclast differentiation. Taken together, we provide the first evidence that $TGF{\beta}1/Smad4$ signaling affects osteoclast differentiation by regulation of miR-155 expression and the use of miR-155 as a potential therapeutic target for osteoclast-related diseases shows great promise.


miR-155;osteoclast differentiation;Smad4;$TGF{\beta}1$


Supported by : Natural Science Foundation of China, Natural Scientific Research Foundation of Zhejiang Medical College, Zhejiang Provincial Health Bureau Science Foundation of China, Zhejiang Provincial Chinese Traditional Medicine Bureau Science Foundation of China


  1. Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zacharioudaki, V., Margioris, A.N., Tsichlis, P.N., and Tsatsanis, C. (2009). The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31, 220-231.
  2. Anumanthan, G., Halder, S.K., Osada, H., Takahashi, T., Massion, P.P., Carbone, D.P., and Datta, P.K. (2005). Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J. Cancer 93, 1157-1167.
  3. Bartel, D.P. (2004). MicroRNAs : genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
  4. Baud'huin, M., Lamoureux, F., Duplomb, L., Redini, F., and Heymann, D. (2007). RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol. Life Sci. 64, 2334-2350.
  5. Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.
  6. Chenu, C., Pfeilschifter, J., Mundy, G.R., and Roodman, G.D. (1988). Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA 85, 5683-5687.
  7. Darcy, A., Meltzer, M., Miller, J., Lee, S., Chappell, S., Ver Donck, K., and Montano, M. (2012). A novel library screen identifies immunosuppressors that promote osteoblast differentiation. Bone 50, 1294-1303.
  8. Dou, C., Zhang, C., Kang, F., Yang, X., Jiang, H., Bai, Y., Xiang, J., Xu, J., and Dong, S. (2014). MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim. Biophys. Acta 1839, 1084-1096.
  9. Elton, T.S., Selemon, H., Elton, S.M., and Parinandi, N.L. (2013). Regulation of the MIR155 host gene in physiological and pathological processes. Gene 532, 1-12.
  10. Engel, M.E., Datta, P.K., and Moses, H.L. (1998). Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J. Cell Biochem. Suppl. 30-31, 111-122.
  11. Feng, H., Cheng, T., Steer, J.H., Joyce, D.A., Pavlos, N.J., Leong, C., Kular, J., Liu, J., Feng, X., Zheng, M.H., et al. (2009). Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis. J. Biol. Chem. 284, 14667-14676.
  12. Franceschetti, T., Kessler, C.B., Lee, S.K., and Delany, A.M. (2013). miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration. J. Biol. Chem. 288, 33347-33360.
  13. Goldring, S.R., and Gravallese, E.M. (2000). Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. 2, 1-5.
  14. Goto, T., Yamaza, T., and Tanaka, T. (2003). Cathepsins in the osteoclast. J. Electron Microsc. (Tokyo) 52, 551-558.
  15. Hattersley, G., and Chambers, T.J. (1991). Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function. J. Bone Miner Res. 6, 165-172.
  16. Hayashi, T., Kaneda, T., Toyama, Y., Kumegawa, M., and Hakeda, Y. (2002). Regulation of receptor activator of NF-kappa B ligandinduced osteoclastogenesis by endogenous interferon-beta (INFbeta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of $SOCSs^-$ in IFN-beta-inhibited osteoclast formation. J. Biol. Chem. 277, 27880-27886.
  17. Houde, N., Chamoux, E., Bisson, M., and Roux, S. (2009). Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J. Biol. Chem. 284, 23397-23404.
  18. Huang, B.P.H. (2014). Smad 1/5 and Smad 4 expression are necessary for osteoclast differentiation. Dissertations & Theses - Gradworks.
  19. Janssens, K., ten Dijke, P., Janssens, S., and Van Hul, W. (2005). Transforming growth factor-beta1 to the bone. Endocr. Rev. 26, 743-774.
  20. Ji, X., Chen, X., and Yu, X. (2016). MicroRNAs in osteoclastogenesis and function: potential therapeutic targets for osteoporosis. Int. J. Mol. Sci. 17, 349.
  21. Jiang, S., Zhang, H.W., Lu, M.H., He, X.H., Li, Y., Gu, H., Liu, M.F., and Wang, E.D. (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70, 3119-3127.
  22. Kagiya, T., and Nakamura, S. (2013). Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation. J. Periodontal Res. 48, 373-385.
  23. Ke, K., Sul, O.J., Rajasekaran, M., and Choi, H.S. (2015). MicroRNA- 183 increases osteoclastogenesis by repressing heme oxygenase-1. Bone 81, 237-246.
  24. Kikuta, J., and Ishii, M. (2013). Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 52, 226-234.
  25. Kim, K., Kim, J.H., Kim, I., Lee, J., Seong, S., Park, Y.W., and Kim, N. (2015). MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol. Cells 38, 75-80.
  26. Kong, W., Yang, H., He, L., Zhao, J.J., Coppola, D., Dalton, W.S., and Cheng, J.Q. (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell Biol. 28, 6773-6784.
  27. Krzeszinski, J.Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.C., Xie, X.J., He, L., Mangala, L.S., Lopez-Berestein, G., et al. (2014). miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512, 431-435.
  28. Lee, Y., Kim, H.J., Park, C.K., Kim, Y.G., Lee, H.J., Kim, J.Y., and Kim, H.H. (2013). MicroRNA-124 regulates osteoclast differentiation. Bone 56, 383-389.
  29. Lu, C., Huang, X., Zhang, X., Roensch, K., Cao, Q., Nakayama, K.I., Blazar, B.R., Zeng, Y., and Zhou, X. (2011). miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood 117, 4293-4303.
  30. Mann, M., Barad, O., Agami, R., Geiger, B., and Hornstein, E. (2010). miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate. Proc. Natl. Acad. Sci. USA 107, 15804-15809.
  31. Mashima, R. (2015). Physiological roles of miR-155. Immunology 145, 323-333.
  32. Massague, J. (1998). TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753-791.
  33. Massague, J., and Wotton, D. (2000). Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19, 1745-1754.
  34. Mizoguchi, F., Murakami, Y., Saito, T., Miyasaka, N., and Kohsaka, H. (2013). miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res. Ther. 15, R102.
  35. Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-Hora, M., Feng, J.Q., Bonewald, L.F., Kodama, T., Wutz, A., Wagner, E.F., et al. (2011). Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234.
  36. O'Connell, R.M., Rao, D.S., and Baltimore, D. (2012). microRNA regulation of inflammatory responses. Ann. Rev. Immunol. 30, 295-312.
  37. Qu, B., Xia, X., Yan, M., Gong, K., Deng, S., Huang, G., Ma, Z., and Pan, X. (2015). miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases. Exp. Cell Res. 338, 89-96.
  38. Schwarte-Waldhoff, I., and Schmiegel, W. (2002). Smad4 transcriptional pathways and angiogenesis. Int. J. Gastrointest Cancer 31, 47-59.
  39. Shinar, D.M., and Rodan, G.A. (1990). Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. Endocrinology 126, 3153-3158.
  40. Takayanagi, H. (2007). Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304.
  41. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901.
  42. Tanaka, S., Takahashi, N., Udagawa, N., Tamura, T., Akatsu, T., Stanley, E.R., Kurokawa, T., and Suda, T. (1993). Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91, 257-263.
  43. Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508.
  44. Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., Koga, T., Martin, T.J., and Suda, T. (1990). Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87, 7260-7264.
  45. Xia, Z., Chen, C., Chen, P., Xie, H., and Luo, X. (2011). MicroRNAs and their roles in osteoclast differentiation. Front Med. 5, 414-419.
  46. Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005). DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202, 345-351.
  47. Yamaguchi, M., and Kishi, S. (1995). Differential effects of transforming growth factor-beta on osteoclast-like cell formation in mouse marrow culture: relation to the effect of zinc-chelating dipeptides. Peptides 16, 1483-1488.
  48. Yang, G., and Yang, X. (2010). Smad4-mediated TGF-beta signaling in tumorigenesis. Int. J. Biol. Sci. 6, 1-8.
  49. Zhang, J., Zhao, H., Chen, J., Xia, B., Jin, Y., Wei, W., Shen, J., and Huang, Y. (2012a). Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett. 586, 3255-3262.
  50. Zhang, L., Sun, H., Zhao, F., Lu, P., Ge, C., Li, H., Hou, H., Yan, M., Chen, T., Jiang, G., et al. (2012b). BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 72, 4276- 4285.
  51. Zhao, Q., Shao, J., Chen, W., and Li, Y.P. (2007). Osteoclast differentiation and gene regulation. Front Biosci. 12, 2519-2529.
  52. Zhao, C., Sun, W., Zhang, P., Ling, S., Li, Y., Zhao, D., Peng, J., Wang, A., Li, Q., Song, J., et al. (2015). miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol. 12, 343-353.

Cited by

  1. Normalization strategies differently affect circulating miRNA profile associated with the training status vol.9, pp.1, 2019,